Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
about
Targeting the androgen receptor in prostate and breast cancer: several new agents in developmentThe HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancerThe HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabineThe HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90Advances in androgen receptor targeted therapy for prostate cancerA multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Androgen receptor splice variants in the era of enzalutamide and abiraterone.ALDH1A3 correlates with luminal phenotype in prostate cancer.Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer CellsAndrogen receptor variation affects prostate cancer progression and drug resistance.BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload.Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.
P2860
Q27009424-AB1E5333-F187-4DF1-893E-EABAED48EE6BQ33912171-61ADA719-A87A-4CE7-AF8D-CD16C70915EEQ35018858-D21AFD0F-28FC-41BE-82AE-1CA03672F9CCQ35598295-9798084C-6763-47C7-A950-10277D730FEBQ35606420-69A01589-86EA-4ACD-84E8-2F93966508DDQ35673943-53EAD260-260C-46AA-91A2-FF173C0C89D2Q35818450-ECC91E17-2BFD-4EA8-A162-DD6FDC5A6A4EQ37093536-ED843CA6-AC11-4FAA-98D3-C1C4741569BAQ37293806-43F13F3A-5E43-4E4D-BE54-33938218B535Q37337217-AE15E4AB-7CFB-4017-9D55-E3B6A7F23A07Q37417712-B7601C8A-9E15-4B26-9BC7-17FFB65A77CCQ37470072-D88FD94C-3FB0-4B72-A1AA-E39CCB0ADC31Q37554911-363993C4-5B96-445C-B8F0-44F186D86AE8Q37737611-11E0CA1C-2D94-4B57-9CE5-F3F1561AE6B8Q38232413-6A02B548-9861-4271-92C7-189970DDB4A1Q38690835-E544869A-6668-48E6-831B-BD6D09F52087Q38697766-B84084ED-337F-4017-892F-067CA33419F7Q38714216-8AB350A3-F541-4508-BD2D-06ED9AB0D6D1Q38759678-AE4F2C5B-6D4A-4598-8D7E-F6485A8CCD9DQ38977288-296CC10C-A197-45BA-B45A-FA3D78E55028Q39263075-08CE3B6F-727A-4581-91A8-B1C12D56C431Q47797544-8DED78B1-1725-4A72-A4B6-84BBDE322D3CQ47811299-4434C3AE-241C-4941-8F3D-826CD39DCE68Q55343985-1C32D358-7D81-4AB0-BE50-D5A4AB620399
P2860
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Potent activity of the Hsp90 i ...... r variant receptor expression.
@ast
Potent activity of the Hsp90 i ...... r variant receptor expression.
@en
type
label
Potent activity of the Hsp90 i ...... r variant receptor expression.
@ast
Potent activity of the Hsp90 i ...... r variant receptor expression.
@en
prefLabel
Potent activity of the Hsp90 i ...... r variant receptor expression.
@ast
Potent activity of the Hsp90 i ...... r variant receptor expression.
@en
P2093
P2860
P356
P1476
Potent activity of the Hsp90 i ...... r variant receptor expression.
@en
P2093
Ayesha A Shafi
Chaohua Zhang
David A Proia
Donald L Smith
Jaime Acquaviva
Julie C Friedland
Manuel Sequeira
Nancy L Weigel
P2860
P356
10.3892/IJO.2012.1698
P577
2012-11-14T00:00:00Z